Top

Published in:

01-09-2009 | Original Article

Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells

Authors: Takeshi Asano, Arisa Tsutsuda-Asano, Yoshitaka Fukunaga

Published in: Cancer Chemotherapy and Pharmacology | Issue 4/2009

Abstract

Drug resistance continues to be a serious problem in cancer therapy. We investigated whether indomethacin, which inhibits cyclooxygenases, is able to overcome doxorubicin resistance in K562/ADR leukemia cells. Indomethacin at 10 μM increased the cytotoxicity of doxorubicin and vincristine in K562/ADR cells. Intracellular glutathione content was elevated in K562/ADR cells. Indomethacin treatment decreased glutathione content and glutathione-conjugates in K562/ADR cells. Increased expression of γ-glutamylcysteine synthetase (γ-GCS) was observed in K562/ADR cells, but this expression was decreased by indomethacin treatment. The activity of the γ-GCS promoter from K562/ADR cells decreased after indomethacin treatment in MDA231 cells. These data strongly suggest that the cyclooxygenase inhibitor indomethacin increases the cytotoxicity of doxorubicin by decreasing the intracellular contents of glutathione and its conjugates with decreasing expression of γ-GCS by inhibiting γ-GCS promoter activity.

Asano T, Zhi C-L, Hayakawa J, Fukunaga Y (2003) Analysis of resistance-related gene expression in doxorubicin resistant leukemia cell line by DNA microarray. Jpn J Pediatr Hematol 17:348–353

Brenner CA, Tam AW, Nelson PA, Engleman EG, Suzuki N, Fry KE, Larrick JW (1989) Message amplification phenotyping (MAPPing): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Bio techniques 7:1096–1103

Cullen KV, Davey RA, Davey MW (2001) Verapamil-stimulated glutathione transport by the mutidrug resistance-associated protein (MRP1) in leukaemia cells. Biochem Pharmacol 62:417–424PubMedCrossRef

van der Holt B, Lowenberg B, Burnett AK, Knauf WU, Shepherd J, Piccaluga PP, Ossenkoppele GJ, Verhoef GEG, Ferrant A, Crump M, Selleslag D, Theobald M, Fey MF, Vellenga E, Dugan M, Sonneveld P, on behalf of the Dutch-Belgian Hemato-Oncology Cooperative Group and the United Kingdom Medical Council. (2005) The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis. Blood 106:2646–2654PubMedCrossRef

Iida T, Kijima H, Urata Y, Goto S, Ihara Y, Ola M, Kohno S, Scanlon KJ, Kondo T (2001) Hammerhead ribozyne against γ-glutamylcysteine synthetase sensitizes human colon cancer cells to cisplatin by downregulating both the glutathione synthesis and the expression of multiple drug resistance protein. Cancer Gene Ther 8:803–814PubMedCrossRef

Ishiwaka T, Wright CD, Ishizuka H (1994) GS-X pump is functionally overexpressed in cis-diamminedichloroplatinum(II)-resistant human leukemia HL-60 cells and down-regulated by cell differentiation. J Biol Chem 269:29085–29093

Ishikawa T, Bao J-J, Yamane Y, Akimaru K, Frindrich K, Wright CD, Kuo MT (1996) Coordinated induction of MRP/GS-X pump and γ-glutamylcysteine synthetase by heavy metals in human leukemia cells. J Biol Chem 271:14981–14988PubMedCrossRef

Kartner N, Riordan JR, Ling V (1985) Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science 316:820–823

van der Kolk DM, de Vries EGE, Muller M, Vellenga E (2002) The role of drug efflux pumps in acute myeloid leukemia. Leuk Lymphoma 43:685–701PubMedCrossRef

10.

Kundu N, Fulton AM (2002) Selective cyclooxygenase (Cox)-1 or Cox-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res 62:2343–2346PubMed

11.

Kruth GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537–7552CrossRef

12.

Kuo MT, Bao J-J, Curley SA, Ikeguchi M, Johnston DA, Ishikawa T (1996) Frequent coordinated overexpression of the MRP/GS-X pump and γ-glutamylcysteine synthetase genes in human colorectal cancers. Cancer Res 56:3642–3644PubMed

13.

Martin F, Pener M-F, Malergue F, Lepidi H, Dessein A, Galland F, de Reggi M, Naquet P, Gharib B (2004) Vanin-1-/- mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest 113:591–597PubMed

14.

Matsunaga S, Asano T, Tsutsuda-Asano A, Fukunaga Y (2006) Indomethacin overcomes doxorubicin resistance with inhibiting Multi-drug resistance protein 1 (MRP1). Cancer Chemother Pharmacol 58(3):348–353PubMedCrossRef

15.

Morales A, Miranda M, Sanchez-Reyes A, Colell A, Biete A, Fernandez-Checa JC (1998) Transcriptional regulation of eavy subunit chain of γ-glutamycysteine synthetase by ionizing radiation. FEBS Lett 447:15–20CrossRef

16.

Noguchi T, Ren X-Q, Aoki S, Igarashi Y, Che X-F, Nakajima Y, Tkahashi H, Mitsuo R, Tsujikawa K, Sumizawa T, Haraguchi M, Kobayashi M, Goto S, Kanehisa M, Aikou T, Akiyama S, Furukawa T (2005) MRP1 mutated in the L₀ region transports SN-38 but not leukotriene C₄ or estradiol-17 (β-d-glucuronate). Biochem Pharmacol 70:1056–1065PubMedCrossRef

17.

Roller A, Baehr O, Streffer J, Winter S, Heneka M, Deininger M, Meyermann R, Naumann U, Gulbins E, Weller M (1999) Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of Cox-1 and MRP. Biochem Biophys Res Commun 259:600–605PubMedCrossRef

18.

Salerno M, Garnier-Sullerot A (2001) Kinetics of glutathione and daunorubicin efflux from multidrug resistance protein overexpressing small-cell lung cancer cells. Eur J Pharmacol 421:1–9PubMedCrossRef

19.

Sales KJ, Katz AA, Howard B, Soeter RP, Millar RP, Jabbour HN, Soeters RP (2002) Cyclooxygenase-1 is up-regulated in cervical carcinomas: Autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin E receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res 62:424–432PubMed

20.

Sedlak J, Lindsay RH (1968) Estimation of total, protein-bound, and non-protein sulfhydryl groups in tissue with Ellman`s reagent. Ana Bioch 25:192–205CrossRef

21.

Takamura Y, Fatman N, Kubo E, Singh DP (2006) Regulation of heavy subunit chain of γ-glutamylcysteine synthetase by tumor necrosis factor-α in lens epitherial cells: role of LEDGF/p75. Am J Physiol Cell Physiol 290:C554–C566PubMedCrossRef

22.

Versantvoort CHM, Broxterman HJ, Bagrij T, Scheper RJ, Twentyman P (1995) Regulation by glutathione of drug transport in multidrug-resistance-associated protein. Brit J Cancer 72:82–89PubMed

23.

Yao K-S, Godwin AK, Johnson SW, Ozols RF, O’Dwyer PJ, Hamilton TC (1995) Evidence for altered regulation of γ-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines. Cancer Res 55:4367–4374PubMed

24.

Zhi H, Zhang J, Hu G, Lu J, Wang X, Zhou C, Wu M, Liu Z (2003) The deregulation of arachidonic acid metabolism-related genes in human esophageal squamous cell carcinoma. Int J Cancer 106:327–333PubMedCrossRef

Title: Indomethacin overcomes doxorubicin resistance by decreasing intracellular content of glutathione and its conjugates with decreasing expression of γ-glutamylcysteine synthetase via promoter activity in doxorubicin-resistant leukemia cells
Authors: Takeshi Asano
Arisa Tsutsuda-Asano
Yoshitaka Fukunaga
Publication date: 01-09-2009
Publisher: Springer-Verlag
Published in: Cancer Chemotherapy and Pharmacology / Issue 4/2009
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-008-0920-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2009

SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples

Protection of mouse bone marrow from etoposide-induced genomic damage by dexrazoxane

A phase I trial of gemcitabine, docetaxel and carboplatin administered every 2 weeks as first line treatment in patients with advanced breast cancer

MTT assays can underestimate cell numbers

Vandetanib with FOLFIRI in patients with advanced colorectal adenocarcinoma: results from an open-label, multicentre Phase I study

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer